One hundred and fifty-six scientists have just published a long letter in various journals explaining why we need to continue with Gain of Function...

Three studies report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers.

This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.”

The Central Dogma of Biology. Biological information flows along a one-way street, or does it? A new paper questions the validity of long-held tennents.